Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland-type lung adenocarcinoma diagnosed due to esophageal stricture: A case report

Keita Kawakado, Tomoki Tamura, Masamoto Nakanishi, Go Makimoto, Yumiko Sato, Shoichi Kuyama

Research output: Contribution to journalArticlepeer-review

Abstract

Primary salivary gland-type tumors of the lung are rare, accounting for <1% of all lung tumors. There are few reports on chemotherapy for the treatment of primary salivary gland-type tumors of the lung. The patient in this report was a 71-year-old woman who presented with a chief complaint of dysphagia. Upper gastrointestinal endoscopy revealed an esophageal stricture, but biopsy showed no malignancy. Chest computed tomography (CT) showed carcinomatous lymphangiomatosis and a nodule in the right lung. Bronchoscopy showed a rough mucous membrane of the central bronchi, while biopsy showed adenocarcinoma. The patient was diagnosed with bronchogenic adenocarcinoma and received carboplatin, pemetrexed, and pembrolizumab, which alleviated the esophageal stricture and cancerous lymphangiopathy. However, the adenocarcinoma progressed, and she subsequently received several rounds of chemotherapy. One year after diagnosis, the patient died, and pathological autopsy revealed primary salivary gland-type tumors of the lung.

Original languageEnglish
Pages (from-to)2513-2516
Number of pages4
JournalThoracic Cancer
Volume12
Issue number18
DOIs
Publication statusPublished - Sep 2021
Externally publishedYes

Keywords

  • carboplatin
  • case report
  • pembrolizumab
  • pemetrexed
  • primary salivary gland-type tumor of the lung

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland-type lung adenocarcinoma diagnosed due to esophageal stricture: A case report'. Together they form a unique fingerprint.

Cite this